PURPOSE:
To evaluate the
efficacy and
toxicity of
docetaxel regimen as second-line after failure of a
platinum-based
chemotherapy.
METHODS:
Between May 2005 and June 2008, we retrospectively analyzed the data of 22
patients who had evidence of
disease progression after one prior
platinum-based regimen for metastatic urothelial
carcinoma.
Patients were treated with two different
docetaxel dose schedules (1)
docetaxel 60 mg/m(2) every 21 days for unfit
patients or (2)
docetaxel 75 mg/m(2) every 21 days for fit
patients.
RESULTS:
Median number of
docetaxel cycles was three. Overall
disease control rate was 18 %. Of the 22
patients, no
patient achieved complete or partial response and four
patients had stable
disease. Median
progression-free survival was 1.67 months and median overall
survival was 3.12 months.
Neutropenia was the most common
adverse event.
CONCLUSIONS:
This study identifies that
docetaxel as second-line
chemotherapy has low activity and was associated with significant
toxicity (AU)
